SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma

Barosi, Giovanni; Merlini, Giampaolo; Billio, Atto; Boccadoro, Mario; Corradini, Paolo; Marchetti, Monia; Massaia, Massimo; Tosi, Patrizia; Palumbo, Antônio; Cavo, Michèle; Tura, S

doi:10.1007/s00277-012-1445-y

Cited by 29 publications

(20 citation statements)

References 68 publications

(75 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The literature search identified twenty-six unique studies: three guidelines based on systematic reviews [7][8][9] , six systematic reviews 5,[10][11][12][13][14] , seventeen rcts 15-31 and forty-seven related publications . Figure 1 shows the study flow chart, and Table i presents the studies with their related publications and objectives.…”

Section: Literature Searchmentioning

confidence: 99%

Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations

Kouroukis

Baldassarre²,

Haynes³

et al. 2014

Current Oncology

104

View full text Add to dashboard Cite

We conducted a systematic review to determine the appropriate use of bortezomib alone or in combination with other agents in patients with multiple myeloma (MM). We searched MEDLINE, EMBASE, the Cochrane Library, conference proceedings, and the reference lists of included studies. We analyzed randomized controlled trials and systematic reviews if they involved adult MM patients treated with bortezomib and if they reported on survival, disease control, response, quality of life, or adverse effects. Twenty-six unique studies met the inclusion criteria. For patients with previously untreated MM and for candidates for transplantation, we found a statistically significant benefit in time to progression [hazard ratio (HR): 0.48, p < 0.001; and HR: 0.63, p = 0.006, respectively] and a better response with a bortezomib than with a non-bortezomib regimen (p < 0.001). Progression-free survival was longer with bortezomib and thalidomide than with thalidomide alone (p = 0.01). In non-candidates for transplantation, a significant benefit in overall survival was observed with a bortezomib regimen (HR compared with a non-bortezomib regimen: 0.61; p = 0.008), and in transplantation candidates receiving bortezomib, the response rate was improved after induction (p = 0.004) and after a first transplant (p = 0.016). In relapsed or refractory MM, overall survival (p = 0.03), time to progression (HR: 1.82; p = 0.000004), and progression-free survival (HR: 1.69; p = 0.000026) were significantly improved with bortezomib and pegylated liposomal doxorubicin (compared with bortezomib alone), and bortezomib monotherapy was better than dexamethasone alone (HR: 0.77; p = 0.027). Bortezomib combined with thalidomide and dexamethasone was better than either bortezomib monotherapy or thalidomide with dexamethasone (p < 0.001). In previously untreated or in relapsed or refractory MM patients, bortezomib-based therapy has

show abstract

Section: Literature Searchmentioning

confidence: 99%

Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations

Kouroukis

Baldassarre²,

Haynes³

et al. 2014

Current Oncology

104

View full text Add to dashboard Cite

show abstract

“…Over the past decade, the survival of patients with multiple myeloma has significantly improved, mainly due to the introduction of the novel immunomodulatory agent lenalidomide, the potent proteasome inhibitor bortezomib, and the application of high-dose conventional therapy with autologous stem cell rescue (1). Nonetheless, virtually all antimyeloma strategies are eventually hampered by the development of drug resistance.…”

Section: Introductionmentioning

confidence: 99%

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

Nijhof

Groen

Noort

et al. 2015

Clinical Cancer Research

136

115

View full text Add to dashboard Cite

Purpose: Novel therapeutic agents have significantly improved the survival of patients with multiple myeloma. Nonetheless, the prognosis of patients with multiple myeloma who become refractory to the novel agents lenalidomide and bortezomib is very poor, indicating the urgent need for new therapeutic options for these patients. The human CD38 monoclonal antibody daratumumab is being evaluated as a novel therapy for multiple myeloma. Prompted with the encouraging results of ongoing clinical phase I/II trials, we now addressed the potential value of daratumumab alone or in combination with lenalidomide or bortezomib for the treatment of lenalidomide-and bortezomib-refractory patients.Experimental Design: In ex vivo assays, mainly evaluating antibody-dependent cell-mediated cytotoxicity, and in an in vivo xenograft mouse model, we evaluated daratumumab alone or in combination with lenalidomide or bortezomib as a potential therapy for lenalidomide-and bortezomib-refractory multiple myeloma patients.Results: Daratumumab induced significant lysis of lenalidomide/bortezomib-resistant multiple myeloma cell lines and of primary multiple myeloma cells in the bone marrow mononuclear cells derived from lenalidomide-and/or bortezomib-refractory patients. In these assays, lenalidomide but not bortezomib, synergistically enhanced daratumumabmediated multiple myeloma lysis through activation of natural killer cells. Finally, in an in vivo xenograft model, only the combination of daratumumab with lenalidomide effectively reduced the tumorigenic growth of primary multiple myeloma cells from a lenalidomide-and bortezomib-refractory patient.Conclusions: Our results provide the first preclinical evidence for the benefit of daratumumab plus lenalidomide combination for lenalidomide-and bortezomib-refractory patients.

show abstract

“…After the advent of proteasome inhibitors, international guidelines agree on first-line treatment strategy for ASCT-eligible and noneligible patients [1–3]. However, selecting and managing the correct therapy for a patient with rrMM it is still a tough task for the hematologist, as, after many relapses, available therapeutic options are scanty.…”

Section: Discussionmentioning

confidence: 99%

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma

Cerchione

Nappi

Perna

et al. 2016

Case Reports in Hematology

View full text Add to dashboard Cite

The clinical management of relapsed/refractory multiple myeloma and the correct choice of the most suitable therapy in heavily pretreated and fragile patients are tough clinical issues for clinicians. In advanced phases of disease, the choice of available therapies becomes very poor, and the retreatment with previously adopted and effective therapy, although unpredictable, could be an effective option. In this report, we describe the clinical history of a patient, previously treated with 9 lines of therapy, refractory to bortezomib and IMIDs, for whom the retreatment with bendamustine resulted in a stable disease with good quality of life.

show abstract

SIE, SIES, GITMO evidence-based guidelines on novel agents (thalidomide, bortezomib, and lenalidomide) in the treatment of multiple myeloma

Cited by 29 publications

References 68 publications

Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations

Bortezomib in Multiple Myeloma: Systematic Review and Clinical Considerations

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

Retreatment with Bendamustine-Bortezomib-Dexamethasone in a Patient with Relapsed/Refractory Multiple Myeloma

Contact Info

Product

Resources

About